Already a Bloomberg.com user?
Sign in with the same account.
Don't have an account?
Help! I can't access my account.
Merck KGaA, the German maker of the cancer drug Erbitux, raised its full year forecast after second-quarter profit rose 14 percent as the euro’s decline boosted sales and demand for medicines increased.
On Air Now
Max 250 characters
©2013 Bloomberg L.P. All Rights Reserved. Made in NYC